$CGEN

Levine Zurit sold $5K of CGEN

Levine Zurit (SVP, Business Development) sold 1,875 shares of COMPUGEN LTD (CGEN) at $2.50 on 2026-07-09 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Levine Zurit
Published Jul 13, 2026, 8:01 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 13, 2026, 8:06 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$CGEN
Neutral
high confidence
Mentioned
$CGEN
Relevance
2/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CGENNeutralLow
01

Why it matters

The only new fact is the officer’s planned open-market sale details; it does not include new operational, financial, or regulatory information about CGEN.

02

Market read

Traders may note the insider sale for sentiment monitoring, but it is unlikely to drive a fundamental repricing.

03

What to watch

The sale size ($4,687.50) is small relative to typical market moves, and the 10b5-1 structure reduces interpretability as a new negative signal.

Relevance 2/10Novelty 3/10Timing: Filed 2026-07-13 after-hours; reflects sale executed 2026-07-09.

Background

The article is an SEC Form 4 insider transaction disclosure for Compugen Ltd (CGEN).

Company-level read

Ticker impact

$CGENNeutralHigh confidence
Context

SEC Form 4 shows CGEN SVP Levine Zurit sold 1,875 shares at $2.50 on 2026-07-09 under a 10b5-1 plan.

Expected impact

Likely minimal impact on CGEN price; any effect is more about liquidity/positioning than new company information.

Evidence & confidence

The filing discloses a small, pre-planned sale by an officer, without any accompanying guidance, deal, or regulatory/operational change.

Market effects

No clear sector read-through from a single planned insider sale.

None indicated.

None indicated.

Counterpoint

Even with 10b5-1, repeated insider selling can coincide with investor caution, so traders may still watch for follow-on selling patterns.

Key entities

  • Compugen Ltd

    Subject of the Form 4 insider transaction disclosure.

  • Levine Zurit

    SVP, Business Development who executed the sale under a 10b5-1 plan.

Related articles

$CGENMed

Compugen Reports Second Quarter 2026 Results

Compugen Ltd. (NASDAQ: CGEN) reported Q2 2026 results and a corporate update. The MAIA-ovarian trial of COM701 is progressing, with median progression-free survival interim data expected in Q1 2027. Partner AstraZeneca presented GEMINI-Hepatobiliary overall survival data for rilvegostomig (median 16.8 months). Cash was about $125.3M, funding operations into 2029. Q2 revenue was ~$2.6M vs ~$1.3M in 2025; net loss ~$7.0M.